6-甲基咪唑并[1,2-a]吡啶-2-甲酸 | 80353-93-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-甲基咪唑并[1,2-a]吡啶-2-甲酸
• 中文别名: 6-甲基咪唑[1,2-a]吡啶-2-甲酸；6-甲基咪唑并[1,2-A]吡啶-2-甲酸；6-甲基咪唑[1,2-A]吡啶-2-甲酸
• 英文名称: 6-methylimidazo<1,2-a>pyridine-2-carboxylic acid
• 英文别名: 6-methylimidazo[1,2-a]pyridine-2-carboxylic acid；6-Methyl-imidazo[1,2-a]pyridine-2-carboxylic acid
• CAS: 80353-93-1
• 化学式: C₉H₈N₂O₂
• mdl: MFCD03425068
• 分子量: 176.175
• InChiKey: RFSQTKHVHYSKLX-UHFFFAOYSA-N

物化性质

• 熔点：
  238-240 °C
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H317
• 危险性防范说明：
  P280
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Methylimidazo[1,2-a]pyridine-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Methylimidazo[1,2-a]pyridine-2-carboxylic acid
CAS number: 80353-93-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8N2O2
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-甲基咪唑并[1,2-a]吡啶-2-甲酸 在 重水 、 copper diacetate 、 palladium diacetate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 N-乙酰甘氨酸 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 N-(3-fluorophenyl)-6-methylimidazo[1,2a]pyridine-3-d-2-carboxamide
  参考文献：
  名称：

  Palladium‐Catalyzed Regiodivergent C‐H Olefination of Imidazo[1,2a]pyridine Carboxamide and Unactivated Alkenes

  摘要：

  摘要尽管在线性和支链乙烯基（杂）炔合成方面取得了显著的成功，但使用单一催化体系进行的反式 C-H 烯化反应仍未得到充分发展。为了克服这一局限性，本文报道了一种 Pd/MPAA 催化的咪唑并[1,2a] 吡啶羧酰胺与未活化的末端烯的区域发散性 C-H 烯化反应，根据烯的电子性质生成支链和线性烯化产物。此外，该方案还可用于以 D2O 为氘源对相应杂环烯进行 C-H 脱氘反应。初步实验研究和计算研究（DFT 研究）表明，通过烯烃插入和 β-酸酐消除步骤，可以控制区域发散的烯化反应。

  DOI：

  10.1002/chem.202302759
• 作为产物：
  描述：

  6-甲基咪唑并[1,2-A]砒啶-2-羧酸乙酯 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 6-甲基咪唑并[1,2-a]吡啶-2-甲酸
  参考文献：
  名称：

  Palladium‐Catalyzed Regiodivergent C‐H Olefination of Imidazo[1,2a]pyridine Carboxamide and Unactivated Alkenes

  摘要：

  摘要尽管在线性和支链乙烯基（杂）炔合成方面取得了显著的成功，但使用单一催化体系进行的反式 C-H 烯化反应仍未得到充分发展。为了克服这一局限性，本文报道了一种 Pd/MPAA 催化的咪唑并[1,2a] 吡啶羧酰胺与未活化的末端烯的区域发散性 C-H 烯化反应，根据烯的电子性质生成支链和线性烯化产物。此外，该方案还可用于以 D2O 为氘源对相应杂环烯进行 C-H 脱氘反应。初步实验研究和计算研究（DFT 研究）表明，通过烯烃插入和 β-酸酐消除步骤，可以控制区域发散的烯化反应。

  DOI：

  10.1002/chem.202302759

文献信息

• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193063A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾患和症状的化合物、组合物和方法。
• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019102494A1

  公开（公告）日：2019-05-31

  The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

  公式I、公式Ia和公式Ib的化合物以及它们的类似物、互变异构体、对映异构体、多态性、水合物、溶剂化物、药物可接受的盐、药物组合物、代谢物和前药在本文件中进行了描述。这些化合物抑制PRMT5，并可作为治疗或改善与细胞生长相关的疾病，如恶性肿瘤、精神分裂症、阿尔茨海默病、帕金森病等的治疗或改善剂。
• 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Peyronel Jean-Francois

  公开号：US20100317688A1

  公开（公告）日：2010-12-16

  Compounds of formula (I): in which: X, R 1 , R 2 , R 3 , and R 4 are as defined in the disclosure, or an acid addition salt thereof; an therapeutic use thereof.

  式(I)的化合物： 其中： X，R1，R2，R3和R4如披露中所定义，或其酸盐；其治疗用途。
• Chemical compounds
  申请人：——

  公开号：US20020077337A1

  公开（公告）日：2002-06-20

  The present invention provides a compound of a formula (I): 1 wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一个式(I)的化合物： 1 其中变量在此处定义；用于制备这种化合物的方法；以及在治疗化学因子（如CCR3）或H1介导的疾病状态中使用这种化合物。
• ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME
  申请人：Jimenenz Hermogenes N.

  公开号：US20100022546A1

  公开（公告）日：2010-01-28

  The present invention provides adamantyl-diamide derivatives of formula (1): wherein R 1 and R 2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.

  本发明提供了公式（1）的脱氢胆酸二酰胺衍生物：其中R1和R2如本文所定义，或其药用可接受的盐；以及使用相同的药物组合物和方法。